W. Marston Linehan
Harvard University · 491 works · 32,257 citations · h-index 76
Top works
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
- Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK -Positive Lung Cancer
- Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
- Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
- Vitamins C and E and Beta Carotene Supplementation and Cancer Risk: A Randomized Controlled Trial
- Recent Advances in Targeting ROS1 in Lung Cancer
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
- Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
- Dietary Fat and Fatty Acids and Risk of Colorectal Cancer in Women
- Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
- Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
- Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
- 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
- Resisting Resistance: Targeted Therapies in Lung Cancer
- Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
- 1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
- 463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up